Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Melano TX is a dermatological product line developed by La Pristine Bioceuticals, primarily indicated for the treatment of melasma and other hyperpigmentation disorders. The product is available in both topical and oral formulations. The **Melano TX Cream** is a combination therapy containing **tranexamic acid**, **kojic acid**, **arbutin**, **magnesium ascorbyl phosphate**, and **vitamin E**. Tranexamic acid acts as a plasminogen inhibitor, which reduces the activity of melanocytes by blocking the interaction between melanocytes and keratinocytes. Kojic acid and arbutin serve as tyrosinase inhibitors, preventing the enzymatic conversion of tyrosine to melanin. Magnesium ascorbyl phosphate provides additional tyrosinase inhibition and antioxidant protection, while Vitamin E acts as a skin-conditioning agent. The **Melano TX Tablet** typically contains tranexamic acid as the primary active ingredient, sometimes in combination with antioxidants like proanthocyanidins, to manage systemic factors contributing to melasma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Melano TX.